Company research
Cabaletta Bio, Inc.
CIK 1759138Updated Sep 27, 2026
SecurityCABA · NASDAQ · equity
CABA price & chart
Loading TradingView…
NASDAQ:CABA on TradingView ↗About the company
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Cabaletta’s lead product candidate, rese-cel, is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy being advanced across the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and connect with us on LinkedIn.
In the news
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 165,083,000Source | 185,046,000Source | 253,650,000Source | 116,968,000Source |
| Property, Plant and Equipment, NetUSD | 1,922,000Source | 2,743,000Source | 2,541,000Source | 2,578,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 82,982,000Source | 163,962,000Source | 193,238,000Source | 81,607,000Source |
| Assets, CurrentUSD | 138,871,000Source | 166,675,000Source | 244,490,000Source | 108,834,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,272,000Source | 2,713,000Source | 3,241,000Source | 2,287,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,431,000Source | 6,315,000Source | 4,910,000Source | 4,991,000Source |
| Other Assets, NoncurrentUSD | 5,159,000Source | 2,293,000Source | 1,709,000Source | 565,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 53,032,000Source | 32,711,000Source | 17,452,000Source | 12,448,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -516,957,000Source | -349,101,000Source | -233,237,000Source | -165,562,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 25,000Source | 0Source | 39,000Source | -47,000Source |
| Stockholders' Equity Attributable to ParentUSD | 112,051,000Source | 152,335,000Source | 236,198,000Source | 104,520,000Source |
| Additional Paid in Capital, Common StockUSD | 628,982,000Source | 501,435,000Source | 469,396,000Source | 270,129,000Source |
| Liabilities and EquityUSD | 165,083,000Source | 185,046,000Source | 253,650,000Source | 116,968,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 50,153,000Source | 27,086,000Source | 15,994,000Source | 9,489,000Source |
| Operating Lease, Liability, CurrentUSD | 3,461,000Source | 3,986,000Source | 3,560,000Source | 2,179,000Source |
| Accounts Payable, CurrentUSD | 6,636,000Source | 4,923,000Source | 4,547,000Source | 2,463,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 2,384,000Source | 1,458,000Source | 2,959,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 133,599,000Source | 163,962,000Source | 241,249,000Source | 106,547,000Source |
| Short-term InvestmentsUSD | 50,617,000Source | 0Source | 48,011,000Source | 24,940,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -167,856,000Source | -115,864,000Source | -67,675,000Source | -52,975,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 20,939,000Source | 19,465,000Source | 11,343,000Source | 6,897,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,550,000Source | 1,011,000Source | 1,675,000Source | -28,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -131,080,000Source | -88,222,000Source | -53,549,000Source | -46,380,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -50,266,000Source | 47,289,000Source | -22,451,000Source | -27,217,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,229,000Source | 2,211,000Source | 687,000Source | 2,453,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 100,347,000Source | 11,677,000Source | 187,631,000Source | 32,982,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -80,980,000Source | -29,276,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,713,000Source | 748,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 19,000Source | -20,000Source | — | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | 532,000Source | 405,000Source | 408,000Source | 685,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 133,599,000Source | 163,962,000Source | 241,249,000Source | 106,547,000Source |
| DepreciationUSD | 1,646,000Source | 1,711,000Source | 1,426,000Source | 1,178,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | 0Source | 149,000Source |
| General and Administrative ExpenseUSD | 29,567,000Source | 27,938,000Source | 19,236,000Source | 14,839,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Investment Income, InterestUSD | 6,031,000Source | 10,025,000Source | 6,985,000Source | 1,164,000Source |
| Net Income (Loss) Attributable to ParentUSD | -167,856,000Source | -115,864,000Source | -67,675,000Source | -52,975,000Source |
| Operating ExpensesUSD | 172,241,000Source | 125,141,000Source | 74,660,000Source | 54,139,000Source |
| Other Operating Income (Expense), NetUSD | 358,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 93,558,000Source | 10,875,000Source | 185,202,000Source | 32,855,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 50,000,000Source | 49,500,000Source | 62,500,000Source | 25,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 14,000Source | 1,430,000Source | 2,321,000Source | 51,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -172,241,000Source | -125,141,000Source | -74,660,000Source | -54,139,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -167,856,000Source | -115,864,000Source | -67,675,000Source | -52,975,000Source |
| Earnings Per Share, BasicUSD per share | -2.1Source | -2.34Source | -1.65Source | -1.81Source |
| Earnings Per Share, DilutedUSD per share | -2.1Source | -2.34Source | -1.65Source | -1.81Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,168,054Source | 5,942,036Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 29,567,000Source | 27,938,000Source | 19,236,000Source | 14,839,000Source |
| Interest ExpenseUSD | 2,004,000Source | 748,000Source | — | — |
| Investment Income, InterestUSD | 6,031,000Source | 10,025,000Source | 6,985,000Source | 1,164,000Source |
| Operating ExpensesUSD | 172,241,000Source | 125,141,000Source | 74,660,000Source | 54,139,000Source |
| Other Operating Income (Expense), NetUSD | 358,000Source | — | — | — |
| Research and Development ExpenseUSD | 142,674,000Source | 97,203,000Source | 55,424,000Source | 39,300,000Source |
Filing attachments
caba-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 caba-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA Priority Review Voucher Registrational RESET-SSc® enrollment in approximately 25 patients with SSc-associated interstitial lung di…
Read attachment ↗caba-ex99_1.htm · 8-K · 2026-06-03
EX-99.1 2 caba-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years First juvenile dermatomyositis (…
Read attachment ↗caba-ex99_2.htm · 8-K · 2026-06-03
EX-99.2 3 caba-ex99_2.htm EX-99.2 Corporate Presentation June 2026 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by Cabaletta Bio, Inc. (“we,” “us,” “our,” “Cabaletta” or the “…
Read attachment ↗d145767dex991.htm · 8-K · 2026-05-04
EX-99.1 4 d145767dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering PHILADELPHIA, May 4, 2026 (GLOBE NEWSWIRE) - Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of commo…
Read attachment ↗d145767dex992.htm · 8-K · 2026-05-04
EX-99.2 5 d145767dex992.htm EX-99.2 EX-99.2 Corporate Presentation May 2026 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by Cabaletta Bio, Inc. (“we,” “us,” “our,” “Cabaletta…
Read attachment ↗caba-ex99_1.htm · 8-K · 2026-04-20
EX-99.1 2 caba-ex99_1.htm EX-99.1 Corporate Presentation April 2026 Exhibit 99.1 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by Cabaletta Bio, Inc. (“we,” “us,” “our,” “Cabaletta” or the …
Read attachment ↗